SL22107: Specialised integrated unit 3: management of respiratory diseases and dermatology
[Page last updated: 26 October 2023]
| Academic Year: | 2023/24 |
| Owning Department/School: | Department of Life Sciences |
| Credits: | 10 [equivalent to 20 CATS credits] |
| Notional Study Hours: | 200 |
| Level: | Intermediate (FHEQ level 5) |
| Period: |
|
| Assessment Summary: | CWSI 15%, CWVG 15%, EXCB 70% |
| Assessment Detail: |
|
| Supplementary Assessment: |
|
| Requisites: | |
| Learning Outcomes: |
By the end of the unit, you will be able to:
1. Describe the aetiology, epidemiology, pathophysiology and clinical symptoms of respiratory diseases and how they are diagnosed and treated.
2. Explain the impact of genetic variation on human health and techniques for its detection and analysis.
3. Explain the pharmacology and mechanisms of action of medicines used for the treatment of respiratory and dermatological conditions and be able to critically evaluate structure-activity relationships, dose-response relationships, biomarkers of treatment and clinical outcomes.
4. Understand the ADME, formulation and manufacturing challenges in the development and production of pulmonary and topical drug delivery systems.
5. Describe the formulation and requirements of inhaled and topical dosage forms and their application in treating respiratory and dermatological conditions.
6. Identify and utilise evidence-based approaches for the management of respiratory diseases and dermatological disorders.
7. Describe the role of the pharmacist in prescribing, administering and monitoring medication for patients with respiratory diseases and dermatological disorders.
8. Evaluate the evidence base for the management of respiratory diseases and dermatological disorders.
9. Make appropriate clinical decisions in support of patients with respiratory diseases and dermatological disorders.
10. Apply structured consultation skills to the conditions studied in this unit. |
| Synopsis: | This unit will provide you with a comprehensive, integrated understanding of the design and development of medicines, their pharmacological actions in the body and the evidence-based approach to treatment of patients with the aim of promoting safe and effective outcomes in respiratory diseases and dermatological disorders. |
| Content: | Clinical Introduction and overview of therapeutic area
Biopharmaceutics of pulmonary drug delivery
Deposition mechanisms in the lung
Inhalation devices
Biopharmaceutics of topical drug delivery to the skin
Dermatological formulations. Emulsions, creams, ointments and other colloidal systems
Biopharmaceutics of nasal, ocular and otic drug delivery
Autonomic nervous system pharmacology
Acute inflammation in respiratory allergy and asthma
Gene transcription, inherited genetic diseases including cystic fibrosis
Stem cells and gene manipulation
Drug design - Steroids, beta agonists, muscarinic antagonist: structure-activity relationships
Asthma, COPD, common upper and lower respiratory tract viral infections, tuberculosis
Inflammatory and infective skin diseases
Wound management and dressings
Dry eye and glaucoma
Clinical decision making in respiratory diseases and dermatology
Simulation and practice-based learning in respiratory disease |
| Course availability: |
SL22107 is a Must Pass Unit on the following courses:Department of Life Sciences
|
Notes:
|